Table 3.

Studies on the performance of MRL in pelvic malignancies

Primary malignancy	Study type/number of patients	Performance of MRL	Reference
Genitourinary	Prospective/30	Sensitivity 100%; specificity 80%	Bellin et al.[37], 1998
Prostate	Prospective comparison with contrast-enhanced CT+standard MRI/80	Sensitivity improved from 35.4% to 90.5% (node by node basis) and 100% (patient by patient basis); specificity improved from 90.4% to 97.8%	Harisinghani et al.[38], 2003
Gynaecological	Prospective/9	Sensitivity 33%, specificity 99% (node by node basis); sensitivity 25%, specificity 80% (patient by patient basis)	Keller et al.[39], 2004
Gynaecological	Prospective comparison with standard MRI/44	Sensitivity improved from 29% to 82–93% (node by node basis) and from 27% to 91–100% (patient by patient basis); specificity >95% maintained	Rockall et al.[40], 2005
Prostate	Prospective comparison with contrast-enhanced CT/375	Sensitivity improved from 34% to 82%; specificity changed from 97% to 93% (patient by patient basis)	Heesakkers et al.[41], 2008
Bladder and prostate	Prospective/21	Sensitivity 80%, specificity 73% (patient by patient basis)	Thoeny et al.[30], 2009